Kadimastem has finished treating its second group of participants in a Phase 1/2a clinical trial testing…
Articles by Alejandra Viviescas, PhD
Aquestive Therapeutics has granted a development and commercialization license to Zambon Pharma for its investigational oral…
Aural Analytics and the Translational Genomics Research Institute (TGen) will collaborate on…
Radicava (edaravone), an intravenous treatment for amyotrophic lateral sclerosis (ALS), is now commercially available in Canada, Mitsubishi Tanabe…
AcuraStem has triggered $3 million in Phase 2 funding from its Small…
High glucose levels might compensate for the toxic effects of an accumulation of TDP-43 — a widely expressed…
AB Science has optimized the design of a Phase 3 confirmatory study for mastinib, its oral treatment for amyotrophic…
A potential therapy for amyotrophic lateral sclerosis (ALS) consisting of an antibody that reduces the abnormal accumulation of the TDP-43 protein improved…
A human-derived antibody that specifically binds to abnormal superoxide dismutase 1 (SOD1) improved the symptoms and delayed disease progression in…
In addition to symptoms of depression, disease progression is one of the strongest influences on health-related quality of life in…